Cytosorbents Corporation

AI Score

0

Unlock

1.03
-0.01 (-0.96%)
At close: Jan 15, 2025, 9:47 AM
undefined%
Bid 1
Market Cap 56.48M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.36
PE Ratio (ttm) -2.86
Forward PE n/a
Analyst Buy
Ask 1.03
Volume 30,023
Avg. Volume (20D) 274,193
Open 1.06
Previous Close 1.04
Day's Range 1.00 - 1.09
52-Week Range 0.70 - 1.59
Beta undefined

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complication...

Sector Healthcare
IPO Date Aug 8, 2006
Employees 186
Stock Exchange NASDAQ
Ticker Symbol CTSO

Analyst Forecast

According to 4 analyst ratings, the average rating for CTSO stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 531.07% from the latest price.

Buy 50.00%
Hold 25.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Cytosorbents Corporation is scheduled to release its earnings on Mar 6, 2025, after market closes.
Analysts project revenue of $9.43M, reflecting a 8.39% YoY growth and earnings per share of -0.07, making a -41.67% decrease YoY.
3 months ago · Source
-10%
CytoSorbents shares are trading lower. The company... Unlock content with Pro Subscription
5 months ago · Source
+17.48%
Cytosorbents shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and announced a price target of $10.